{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:33Z","timestamp":1786986873749,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.clinthera.2008.08.006","type":"journal-article","created":{"date-parts":[[2008,9,17]],"date-time":"2008-09-17T07:45:21Z","timestamp":1221637521000},"page":"1448-1460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":283,"title":["Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug\u2014naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study"],"prefix":"10.1016","volume":"30","author":[{"given":"Thomas J.","family":"Moretto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Den\u00e1i R.","family":"Milton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry D.","family":"Ridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh A.","family":"MacConell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Okerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Wolka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Brodows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2008.08.006_bib1","first-page":"S47","article-title":"New technologies and therapies in the management of diabetes","volume":"13","author":"Triplitt","year":"2007","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2008.08.006_bib2","series-title":"Byetta (exenatide) injections [prescribing information]","year":"2008"},{"key":"10.1016\/j.clinthera.2008.08.006_bib3","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2008.08.006_bib4","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2008.08.006_bib5","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2008.08.006_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-146-7-200704030-00003","article-title":"The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial [published correction appears in Ann Intern Med 2007;146:896]","volume":"146","author":"Zinman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2008.08.006_bib7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2008.08.006_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00125-006-0510-2","article-title":"A comparison of twice- daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study","volume":"50","author":"Nauck","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2008.08.006_bib9","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.clinthera.2007.11.006","article-title":"Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial","volume":"29","author":"Barnett","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2008.08.006_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ecl.2004.12.002","article-title":"Glycemic management of type 2 diabetes: An emerging strategy with oral agents, insulins, and combinations","volume":"34","author":"Riddle","year":"2005","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.clinthera.2008.08.006_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079908X253870","article-title":"Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years","volume":"24","author":"Klonoff","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2008.08.006_bib12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1089\/dia.2005.7.467","article-title":"Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: A dose-ranging study","volume":"7","author":"Poon","year":"2005","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.clinthera.2008.08.006_bib13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/dia.2006.0024","article-title":"The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes","volume":"9","author":"Nelson","year":"2007","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.clinthera.2008.08.006_bib14","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1001\/jama.284.23.3043","article-title":"Ethical principles for medical research involving human subjects","volume":"284","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2008.08.006_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clinthera.2005.02.008","article-title":"A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4)","volume":"27","author":"Calara","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2008.08.006_bib16","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2008.08.006_bib17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diab.27.2.102","article-title":"A high-performance liquid chromatography method for hemoglobin A1c","volume":"27","author":"Davis","year":"1978","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2008.08.006_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0026-0495(78)90109-9","article-title":"A rapid method for the determination of glycosylated hemoglobins using high pressure liquid chromatography","volume":"27","author":"Cole","year":"1978","journal-title":"Metabolism"},{"key":"10.1016\/j.clinthera.2008.08.006_bib19","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.2337\/diacare.26.8.2370","article-title":"Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and\/or sulfonylurea treatment in patients with type 2 diabetes","volume":"26","author":"Fineman","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2008.08.006_bib20","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1080\/01621459.1986.10478364","article-title":"The maximum familywise error rate of Fisher's least significant difference test","volume":"81","author":"Hayter","year":"1986","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.clinthera.2008.08.006_bib21","series-title":"Applied Regression Analysis and Other Multivariable Methods","year":"1998"},{"key":"10.1016\/j.clinthera.2008.08.006_bib22","series-title":"Linear Mixed Models for Longitudinal Data","year":"2001"},{"key":"10.1016\/j.clinthera.2008.08.006_bib23","series-title":"Categorical Data Analysis Using the SAS System","author":"Stokes","year":"1995"},{"key":"10.1016\/j.clinthera.2008.08.006_bib24","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM199511093331901","article-title":"Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy","volume":"333","author":"de Veciana","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.08.006_bib25","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.2337\/diacare.23.9.1236","article-title":"Therapy focused on lowering post-prandial glucose, not fasting glucose, may be superior for lowering HbA1c","volume":"23","author":"Bastyr","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2008.08.006_bib26","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)12131-1","article-title":"Glucose tolerance and mortality: Comparison of WHO and American Diabetic Association diagnostic criteria","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2008.08.006_bib27","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1152\/ajpendo.2001.281.1.E155","article-title":"Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers","volume":"281","author":"Edwards","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2008.08.006_bib28","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1210\/endo.141.6.7490","article-title":"Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats","volume":"141","author":"Szayna","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2008.08.006_bib29","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2337\/diacare.26.10.2929","article-title":"Enhancing incretin action for the treatment of type 2 diabetes","volume":"26","author":"Drucker","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2008.08.006_bib30","first-page":"1903","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies [published correction appears in Lancet 2003;361:1060]","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808002725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808002725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:47:56Z","timestamp":1758962876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291808002725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0149291808002725"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.08.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug\u2014naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}